UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036347
Receipt number R000041402
Scientific Title Prospective observational study on intestinal microbiota and gene mutations and gene expressions in colorectal cancer and inflammatory bowel disease
Date of disclosure of the study information 2019/03/29
Last modified on 2019/03/29 19:35:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective observational study on intestinal microbiota and gene mutations and gene expressions in colorectal cancer and inflammatory bowel disease

Acronym

Prospective observational study on intestinal microbiota and gene mutations and gene expressions in colorectal cancer and inflammatory bowel disease

Scientific Title

Prospective observational study on intestinal microbiota and gene mutations and gene expressions in colorectal cancer and inflammatory bowel disease

Scientific Title:Acronym

Prospective observational study on intestinal microbiota and gene mutations and gene expressions in colorectal cancer and inflammatory bowel disease

Region

Japan


Condition

Condition

colorectal cancer and inflammatory bowel disease

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The purpose of this study is to examine the association between intestinal microbiota and colorectal cancer and inflammatory bowel disease.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The association of intestinal microbiota with gene mutations and gene expressions and clinicopathological factors in colorectal cancer and inflammatory bowel disease.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

#1 Patients diagnosed colorectal cancer or inflammatory bowel disease by colonoscopy, computed tomography, and magnetic resonance imaging and scheduled to undergo surgery or colonoscopy.
#2 Age of patient is over 20 years old.
#3 Informed consent can be obtained.

Key exclusion criteria

#1 Informed consent can not be obtained.
#2 Doctor recognizes that patient is not suitable for this study.
#3 Cases in which the lesion is very small and subsequent pathological diagnosis is considered difficult.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Shozo
Middle name
Last name Yokoyama

Organization

Wakayama Medical University

Division name

Second Department of Surgery

Zip code

641-8510

Address

811-1 Kimiidera, Wakayama 641-8510 Japan

TEL

073-441-0613

Email

yokoyama@wakayama-med.ac.jp


Public contact

Name of contact person

1st name Shozo
Middle name
Last name Yokoyama

Organization

Wakayama Medical University

Division name

Second Department of Surgery

Zip code

641-8510

Address

811-1 Kimiidera, Wakayama 641-8510 Japan

TEL

073-441-0613

Homepage URL


Email

yokoyama@wakayama-med.ac.jp


Sponsor or person

Institute

Wakayama Medical University, Second Department of Surgery

Institute

Department

Personal name



Funding Source

Organization

Wakayama Medical University, Second Department of Surgery

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Kindai University School of Medicine, Department of Genome Biology
Wakayama Medical University, Second Department of Internal Medicine

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Independent ethics committee of Wakayama Medical University

Address

811-1 Kimiidera, Wakayama 641-8510 Japan

Tel

073-447-2300

Email

wa-rinri@wakayama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 03 Month 29 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 09 Month 05 Day

Date of IRB

2017 Year 09 Month 05 Day

Anticipated trial start date

2017 Year 09 Month 06 Day

Last follow-up date

2022 Year 09 Month 05 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective observational study


Management information

Registered date

2019 Year 03 Month 29 Day

Last modified on

2019 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041402


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name